The COMP360 topline PR will overstate durability relative to the actual relapse/re-emergence data, and a critical outlet or analyst will document the spin-vs-substance gap within 3 weeks.

When COMPASS announces its two-dose psilocybin trial results, the official press release will likely emphasize the positive findings and downplay how many patients relapsed or left the study. This is a common pattern in pharmaceutical announcements — companies lead with the best news. But within three weeks, at least one journalist or financial analyst will dig into the actual scientific data and write about the gap between what the press release claimed and what the numbers really show.

Every psychedelic readout has a PR-versus-methods gap. Two-administration framing invites scrutiny about single-dose failure. I'll be reporting that story.